Make your money go further for just 25p per day

AIM IHT

Novacyt: on these numbers, the cheapest stock on the market

Novacyt Versalab image

AIM’s top performer from 2020 announces fabulous numbers, but that was last year, what of the future?


Novacyt (EURONEXT GROWTH: ALNOV; LON: NCYT ), the clinical diagnostics specialist and superstar performer from 2020, updated on trading for the year ending 31 December 2020. Here are the astonishing highlights from an incredible year:


Revenue +2400% to €311.6m (£277.0m) including revenue in the second half of the year of €239.2m (£213.7m).
EBITDA profitability above €210m (£187m), representing an EBITDA margin of more than 67%, after adding 124 people to the payroll.
Cash at 31 December 2020 was…

Sign up and read the full article

Register to continue reading our content.

Get FREE access now

Already a member? Login

Fundamental Asset Management
Buy any of our portfolios with our associates.
 

FIND OUT MORE

Previous article Next article

Have your say

Log in or register to view or add comments.

For access to the top news and insights from the investment world

REGISTER FREE

Become a Champion Investor for just £90 a year.
 
 

START FREE TRIAL

More on Novacyt SA

Investing success and new assays

02/02/2021 · Company Insights

After a volatile start to 2021, the share price of last year’s top AIM performer received…


Novacyt: on these numbers, the cheapest stock on the market

29/01/2021 · Company Insights

AIM’s top performer from 2020 announces fabulous numbers, but that was last year, what of the…


More Company Insights

Time to buy the advertising giant?

01/03/2021 · WPP

Investing for growth

01/03/2021

Stonking Small Caps: impressive growth here

26/02/2021